- 首页
- NO Synthase
- Fosifloxuridine nafalbenamide
Fosifloxuridine nafalbenamide
Fosifloxuridine nafalbenamide (NUC-3373) 属于嘧啶核苷酸类似物，是一种胸腺嘧啶合酶 (Thymidylate synthase) 抑制剂。Fosifloxuridine nafalbenamide 具有抗癌活性。Fosifloxuridine nafalbenamide 具有诱发宿主免疫反应和增强免疫治疗的潜力。
此产品仅用于科学研究，我们不为任何个人用途提供产品和服务
-
包装价格促销价数量
-
5mg￥2775.002220.00- +
-
10mg￥3987.003190.00- +
-
25mg￥7987.006390.00- +
-
50mg￥11962.009570.00- +
-
100mg￥17950.0014360.00- +
- 货号: ajcx34134
- CAS: 1332837-31-6
- 别名: NUC-3373
- 分子式: C29H29FN3O9P
- 分子量: 613.53
- 纯度: ＞98%
- 溶解度: DMSO : 100 mg/mL (162.99 mM; Need ultrasonic)
- 储存: Store at -20°C
- 库存: 现货
Background
Fosifloxuridine nafalbenamide (NUC-3373), a pyrimidine nucleotide analogue, is a Thymidylate synthase inhibitor. Fosifloxuridine nafalbenamide has anticancer activity. Fosifloxuridine nafalbenamide has the potential to evoke a host immune response and enhance immunotherapy[1][2].
Fosifloxuridine nafalbenamide induces the release of damage-associated molecular patterns (DAMPs), with increased expression of calreticulin (CRT) at the cell surface and concomitant loss of nuclear nuclear high mobility group box protein 1 (HMGB1)[1].
Fosifloxuridine nafalbenamide exhibits anti-cancer activity in HT-29 nude mouse xenograft models[2].
[1]. Fiona G. McKissock, et al. Abstract 1848: NUC-3373 induces ER stress and the release of damage associated molecular patterns in colorectal cancer cells. Cancer Res August 15 2020 (80) (16 Supplement) 1848.
[2]. Essam A. Ghazaly, et al. Abstract B46: NUC-3373: A novel pyrimidine nucleotide analogue that overcomes key cancer drug resistance limiting patient survival. Mol Cancer Ther December 1 2015 (14) (12 Supplement 2) B46.
